Despite COVID-19 pandemic first patient undergoes new personalized immunotherapy

(University of California - San Diego) Bernard Thurman was referred to a personalized cancer therapy trial at Moores Cancer Center at UC San Diego Health, a collaboration with the La Jolla Institute for Immunology, the trial employs a patient's immune cells -- specifically tumor infiltrating lymphocytes (TIL) -- to destroy cancer cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news